Immunic AG – Home

Immunic is a specialist in selective oral drugs in immunology and focused on developing novel oral therapies with best-in-class potential for chronic inflammatory and autoimmune diseases.

Immunic is based in the Munich biotech hub Martinsried and currently develops three products for the treatment of chronic inflammatory and autoimmune diseases including e.g. inflammatory bowel disease and psoriasis. IMU-838 is currently being tested in a phase 2b trial in patients suffering from ulcerative colitis. A second phase 2 trial in patients with Crohn’s disease is planned to start in mid-2019. IMU-935 is a best-in-class inverse agonist of the nuclear receptor RORγt and currently in preclinical development. IMU-856 is a newly developed and orally available small molecule aiming at a yet undisclosed target and currently in preclinical testing.

Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company

San Diego, CA, USA and Planegg-Martinsried, Germany, January 7, 2019 – Vital Therapies, Inc. (Nasdaq: VTL), and Immunic AG (Immunic), a private clinical-stage biotechnology company in Planegg-Martinsried, Germany, today announced that they ...
Read More

Immunic enters into a global option and license agreement with Daiichi Sankyo

Immunic AG gains exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel disease Planegg-Martinsried, Germany, November 5th, 2018 – Immunic AG (Immunic Therapeutics), ...
Read More

Immunic Reports Start of Enrollment into Clinical Phase 2 Study with IMU-838 in Patients with Ulcerative Colitis

Planegg-Martinsried, Germany, April 26th, 2018 – Immunic AG (Immunic Therapeutics), a clinical stage biotech company in Martinsried near Munich, Germany, today announced that it has started the clinical Phase 2 ...
Read More